Vertex Pharmaceuticals (VRTX) Revenue & Quarterly History
Explore Vertex Pharmaceuticals Incorporated (VRTX) revenue from 2023 through the latest reported quarter, with SEC-sourced comparisons and filing-constrained analysis.
Key takeaway
Quarter ended Mar 31, 2026 · FY2026 Q1
Total revenue decreased from the prior quarter but increased compared to the same quarter last year. The reported revenue for the quarter ending March 31, 2026 declined sequentially, while year-over-year growth continued.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3B
Revenue reported for this quarter.
Quarter-over-quarter
-6.4%
Change from the immediately preceding quarter.
Year-over-year
+7.8%
Change from the comparable year-ago quarter.
Trailing four quarters
$12.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2025 | $3B | +12.1% |
| Sep 30, 2025 | $3.1B | +11.0% |
| Dec 31, 2025 | $3.2B | +9.5% |
| Mar 31, 2026 | $3B | +7.8% |
Revenue performance
Net product revenues drove the quarterly result, with other revenues absent in the current period versus a nominal amount a year earlier. The sequential decline in total revenue was primarily attributable to a reduction in product revenues from the immediately preceding quarter.
Quarterly comparison
Compared to the immediately preceding quarter, total revenue contracted. Relative to the same quarter one year earlier, total revenue rose, reflecting higher product revenues year over year.
What to watch
The sequential revenue decline warrants monitoring for sustained momentum, especially given the absence of other revenues this quarter.